ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year
ImmunoPrecise and Genmab enter into a technology partnership targeting infectious diseaseImmunoPrecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical...